British Patient Capital

As we’re celebrating 10 years of British Business Bank's impact across the UK, we’re looking back at some of the most impactful companies we’ve backed. One of the unicorns in our portfolio, fintech Thought Machine is helping modernise banking technology to make processes easy and efficient for the banks and their customers 🦄 We chatted to CEO and founder Paul Taylor about UK fintech and the role the British Business Bank has played in the industry and their own journey 👇

It’s great to see our impact on biotech highlighted in BioIndustry Association (BIA)'s financig 2024 report. We were the most active UK investor in Series A and the second top investor in Series B in 2024. Our Future Fund: Breakthrough was also involved in three out of 10 top venture capital deals of the year - Myricx Bio, Purespring Therapeutics and Nuclera 🚀 The UK has a strong life sciences sector with high potential, and with programmes like our Life Sciences Investment Programme we want to help increase the availability of later-stage finance for UK life sciences companies so they can thrive. Read more insights about biotech and life sciences funding here: https://bit.ly/4ghyVm7

🔬 Life sciences is at the heart of the UK’s innovation economy, driving breakthroughs that improve lives and strengthen our future. We’re proud to support pioneering companies in this sector. One such company is OMass Therapeutics, backed by our Future Fund: Breakthrough programme. Watch Ros Deegan, CEO of OMass Therapeutics talk to us about: 💡 The challenges and opportunities in life sciences 🌟 The company’s journey to success 🤝 How our support played a vital role in their growth

The UK has a strong life sciences sector with high potential and we want to help increase the availability of later-stage finance for UK life sciences companies so they can thrive 🚀 We're proud to have invested in OMass Therapeutics and support their imporant mission.

BioIndustry Association (BIA)’s biotech financing report 2024 is out, showing the industry secured £2.06 bn venture capital funding – a 64.8% increase from 2023 👏 It’s great to see our impact on biotech highlighted in this report. We were the most active UK investor in Series A and the second top investor in Series B in 2024. Our Future Fund: Breakthrough was also involved in three out of 10 top venture capital deals of the year - Myricx Bio, Purespring Therapeutics and Nuclera 🚀 The UK has a strong life sciences sector with high potential, and with programmes like our Life Sciences Investment Programme we want to help increase the availability of later-stage finance for UK life sciences companies so they can thrive. Read more insights about biotech and life sciences funding here: https://bit.ly/4ghyVm7

British Business Bank is celebrating its 10th anniversary 🎉 We are proud to have played a role in the Bank's impact on UK businesses. Since inception, British Patient Capital has committed £2.3bn to 80 funds, 10 co-investments and 18 Future Fund: Breakthrough investments. To mark the occasion the Bank has published The Power of 10 report looking back at its impact in the last 10 years. Read it here: https://lnkd.in/dwJvx6eM

As well as being the UK's largest domestic investor in UK ventures, we’re also one of the top 10 most active LPs in Europe, according to Sifted.   We made commitments to 82 funds within the 2015-2025 time period Sifted have looked at, making us the 5th most active in Europe 💪 We look forward to building on this momentum in the years ahead, driving even greater impact for the UK’s most innovative businesses 🚀 Read more 👇

Life sciences and biotech present a huge opportunity for the UK and we’re proud to have backed some of the fastest growing companies that make a big difference to our healthcare and society 🔬 It’s great to see companies we’ve backed on The Times’ Tech 100 'Biotech - Ones to Watch' list. Congratulations to Curve Therapeutics, Purespring Therapeutics and Quell Therapeutics for being recognised! 👏 https://lnkd.in/eExirhPN

As the largest domestic investor into UK venture and venture growth opportunities, we back some of most the innovative, high-growth companies in the UK. Fantastic to see a variety of our portfolio among the 100 fastest-growing tech companies highlighted by the The Times, including two of our direct investments, Wagestream and Perspectum Ltd. Congratulations! 👏

#FridayInspiration Against the backdrop of stereotypes, women in VC leadership aren't just challenging norms but reshaping them. Gender isn't a barrier; it's a catalyst for innovation and growth, says Dr. Rabab Nasrallah of Earlybird Venture Capital 🌍💪 #VentureCapital #WomenInSTEM #DiversityMatters